A randomized double-blind trial of ioversol and iopamidol in contrast-enhanced computed body tomography

The authors compared iopamidol and ioversol in a double-blind study conducted on 81 patients (ioversol in 40 patients; iopamidol in 41 patients) undergoing computed body tomography (CT) for a variety of indications at the Flinders Medical Centre in South Australia. Each study was assessed for image quality and rated as diagnostic or nondiagnostic. Patients were monitored for blood pressure measurement, pulse rate, and respiration rate before and after contrast administration and were observed for the occurrence of side effects. Subjective assessments of heat and pain sensations also were obtained from the patients. With the exception of one patient studied with iopamidol, all investigations were rated as either good or excellent. In all cases, the examination was considered diagnostic. No adverse reactions were noted after administration of either contrast material, except in one patient who felt nauseated. Because the patient had reported feeling nauseated before the examination, this side effect was considered to be coincidental. One patient experienced mild pain from injection of iopamidol. In no cases were any drug-related or clinically significant changes in vital signs noted. In this study, both iopamidol and ioversol were well tolerated and effective, with few side effects after intravenous administration for contrast enhancement during whole-body CT.